title: [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
abstract: The purpose of the present multi-center collaborative study was to elucidate the efficacy of intraportal chemotherapy with the combination of 5-FU and MMC for the prevention of liver recurrence after resection for colorectal cancer. A total of 125 patients with Stage II, III, and IV colorectal cancer were enrolled in this study between June 1993 and December 1995. Of them, 45 patients were randomized to a portal group: 10 mg/body of mitomycin one shot portal infusion, before and after 500 mg/m2 of 5-FU per 24 h for 7 days portal infusion followed by administration of oral 5-FU. Fifty-three patients were randomized to a control group: oral administration of 5-FU. Twelve patients suffered from temporary mild liver damage. One patient (2%) in the portal group and 6 patients (11%) in the control group developed liver metastases; there was not a significant difference between these two groups regarding development of liver metastases. There was also no significant difference by tumor stage between the portal and control groups regarding development of liver metastases. The 5-year survival rate and 5-year disease-free survival were 84.3% and 81.9%, respectively, in the portal group, and 70.7% and 72.4%, respectively, in the control group; the difference was not significant. Although there was not a significant difference between the portal and control groups regarding the prognosis in stage II, there was a significant difference between the portal and control groups regarding the 5-year disease free survival in stage III (81.1% vs 54.2%). These results suggest that intraportal chemotherapy is effective for stage III colorectal cancer.
authors.affiliation: Dept. of Surgery, St. Marianna University School of Medicine.
authors.forename: Takuya
authors.initials: T
authors.lastname: Yamamura
authors.forename: Kiyotoshi
authors.initials: K
authors.lastname: Yabe
authors.forename: Hisashi
authors.initials: H
authors.lastname: Oka
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kouzuma
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kawahara
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Wakayama
authors.forename: Arishige
authors.initials: A
authors.lastname: Sugiura
authors.forename: Masaru
authors.initials: M
authors.lastname: Hagiwara
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ohdate
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Miyajima
authors.forename: Chousei
authors.initials: C
authors.lastname: Maeda
authors.forename: Ryuichiro
authors.initials: R
authors.lastname: Okamura
authors.forename: Tooru
authors.initials: T
authors.lastname: Miyahara
authors.forename: Yuukichi
authors.initials: Y
authors.lastname: Moriyama
authors.forename: Susumu
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Atsuaki
authors.initials: A
authors.lastname: Gunji
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D011169:Portal Vein; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D008937:Mitomycins; D005472:Fluorouracil